Materialise (NasdaqGS:MTLS) Stock Price Sinks As Q3 Results Squeeze Profit

Materialise came into Q3 2026 with a reputation as a margin-improving 3D printing specialist and a stock that had quietly outperformed over the past three months. That story met a brutal reset as investors marked the shares down about 21% to €6.78 in the first session after the release. The headline result was simple and uncomfortable. Quarterly revenue landed at €67.67m while basic earnings per share slipped to €0.02379 and net income dropped to €1.376m, signaling a clear squeeze on profitability that jarred with the prior year of strong earnings momentum.

Love Materialise’s 3D printing niche but concerned by the latest squeeze on earnings and the sharp share price reaction? Check out our screener of companies that pair specialist technology with sturdier profitability profiles in the 30 resilient stocks with low risk scores

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): €67.67m vs. €66.259m (up about 2%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): €1.376m vs. €1.848m (down about 26%)
• Basic EPS (Q3 2026 vs. Q3 2025): €0.02379 vs. €0.031286 (down about 24%)
• Net Profit Margin (Trailing 12 Months vs. Prior Year): 4.6% vs. 1.7% (margin level materially higher)

Series manufacturing jumped over 30% even as segment revenue fell. Ask Charlie what’s driving Materialise’s surge in series production.

Materialise’s High‑Value Medical Bet Starts To Show

The bullish story around Materialise hinges on higher value medical and software offerings reshaping the mix toward richer economics.

"The launch of custom-made PEEK cranio-maxillofacial implants and OrthoView 3D Hip extends the medical portfolio into higher value, clinically integrated solutions that can support mix improvement and higher margin contribution within Medical Devices and Medical Software revenue."

Q3 results show that ambition starting to register in the numbers. Medical delivered about 10% revenue growth with adjusted EBITDA of €10m and a 27.4% margin. That combination of double digit top line expansion and high profitability indicates the newer, clinically integrated offerings are helping lift the overall quality of the medical revenue mix, even as group earnings came under pressure.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Materialise Bear Case: Growth Engines Hitting Friction

The cautious view argues that Materialise’s growth engines could stall as customers tighten budgets or delay workflow changes.

"While the shift toward more automated, cloud-based 3D printing workflows through CO-AM Professional aligns with broader digitisation of manufacturing, slower customer onboarding or resistance to platform changes could restrict subscription uptake and recurring software revenue."

Q3 results give this concern real weight. Software revenue declined about 4% to €9.9m and segment EBITDA margin slipped to 15% despite recurring revenue reaching roughly 84% of Software sales. Extended sales cycles for CO-AM and cautious spending were explicitly cited. Medical’s 10% growth helps offset the drag, but it does not yet disprove the Software execution risk.

Hunt Quiet Disconnects In Plain Sight

Materialise just showed how quickly sentiment can shift when earnings momentum runs into margin pressure. The real opportunity is finding stocks that could be undervalued before expectations and business conditions move closer together.

• Company 1 - 46% below our estimate - turns a strong construction backlog and multiple large projects into a test of delivery under rising labor costs and legal disputes.
• Company 2 - 34% below our estimate - expands high horsepower engine capacity so data center and power customers can secure long term supply backed by prior execution.
• Company 3 - 40% below our estimate - builds protective film and installation capability targeting higher margin services as vehicle dealers and installers bundle paint protection into standard offerings.

Those are three of them. See all 29 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com